Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $12.31, for a total value of $24,620.00. Following the transaction, the president now owns 2,831,260 shares of the company's stock, valued at $34,852,810.60. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.09, for a total value of $24,180.00.
• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.74, for a total value of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total value of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total value of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.90, for a total value of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.62, for a total value of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total value of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total value of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.

Gyre Therapeutics Trading Down 4.4 %

Shares of Gyre Therapeutics stock traded down $0.45 on Friday, hitting $9.78. 87,455 shares of the company were exchanged, compared to its average volume of 80,302. The company has a 50-day moving average price of $11.31 and a 200 day moving average price of $12.23. Gyre Therapeutics, Inc. has a 1-year low of $8.26 and a 1-year high of $19.00.

Remove Ads

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million for the quarter, compared to analyst estimates of $23.50 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Wall Street Analysts Forecast Growth

Separately, Noble Financial began coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating on the stock.

Institutional Trading of Gyre Therapeutics

Several institutional investors have recently made changes to their positions in GYRE. SBI Securities Co. Ltd. purchased a new stake in shares of Gyre Therapeutics during the 4th quarter valued at approximately $1,225,000. Charles Schwab Investment Management Inc. raised its position in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock valued at $1,425,000 after buying an additional 90,557 shares during the period. Geode Capital Management LLC raised its position in shares of Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after buying an additional 43,840 shares during the period. Advantage Alpha Capital Partners LP purchased a new stake in shares of Gyre Therapeutics during the 3rd quarter valued at approximately $334,000. Finally, Northern Trust Corp raised its position in shares of Gyre Therapeutics by 9.1% during the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after buying an additional 8,624 shares during the period. Hedge funds and other institutional investors own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.